Integrated Biopharma, Inc.
INBP
$0.30
$0.00-0.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.06% | 4.72% | 8.02% | 4.67% | 3.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.06% | 4.72% | 8.02% | 4.67% | 3.18% |
| Cost of Revenue | 2.07% | 3.47% | 5.08% | 1.21% | -0.25% |
| Gross Profit | -19.83% | 17.79% | 43.20% | 49.94% | 51.64% |
| SG&A Expenses | -3.70% | -3.06% | -2.50% | -3.12% | -2.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.66% | 3.00% | 4.53% | 0.90% | -0.44% |
| Operating Income | -60.18% | 112.96% | 704.78% | 2,645.83% | 478.33% |
| Income Before Tax | -52.23% | 114.43% | 669.40% | 3,085.71% | 494.31% |
| Income Tax Expenses | 70.97% | 178.87% | 703.85% | 1,083.02% | 3,193.75% |
| Earnings from Continuing Operations | -122.20% | 56.28% | 621.43% | 1,181.03% | 341.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.20% | 56.28% | 621.43% | 1,181.03% | 341.04% |
| EBIT | -60.18% | 112.96% | 704.78% | 2,645.83% | 478.33% |
| EBITDA | -50.31% | 80.18% | 318.46% | 781.97% | 3,150.00% |
| EPS Basic | -119.81% | 55.24% | 624.32% | 1,164.10% | 338.76% |
| Normalized Basic EPS | -54.87% | 109.94% | 658.93% | 3,084.62% | 505.26% |
| EPS Diluted | -138.64% | 53.15% | 618.92% | 1,158.97% | 338.76% |
| Normalized Diluted EPS | -55.48% | 113.94% | 701.92% | 2,620.00% | 490.91% |
| Average Basic Shares Outstanding | 2.12% | 1.45% | 0.77% | 0.47% | 0.42% |
| Average Diluted Shares Outstanding | 0.98% | 2.17% | 2.11% | 1.63% | 0.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |